+44 1478 350008Journal of Hematology & Thromboembolic Diseases : Citations & Metrics Report
Articles published in Journal of Hematology & Thromboembolic Diseases have been cited by esteemed scholars and scientists all around the world. Journal of Hematology & Thromboembolic Diseases has got h-index 16, which means every article in Journal of Hematology & Thromboembolic Diseases has got 16 average citations.
Following are the list of articles that have cited the articles published in Journal of Hematology & Thromboembolic Diseases.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total published articles |
40 | 65 | 62 | 50 | 23 | 6 | 15 | 27 | 26 | 56 | 70 | 25 |
Research, Review articles and Editorials |
6 | 19 | 17 | 27 | 8 | 5 | 7 | 21 | 18 | 37 | 59 | 21 |
Research communications, Review communications, Editorial communications, Case reports and Commentary |
28 | 46 | 39 | 23 | 14 | 1 | 5 | 6 | 8 | 14 | 24 | 4 |
Conference proceedings |
0 | 6 | 35 | 35 | 0 | 0 | 41 | 25 | 33 | 0 | 0 | 0 |
Citations received as per Google Scholar, other indexing platforms and portals |
82 | 96 | 141 | 153 | 144 | 131 | 107 | 118 | 119 | 66 | 40 | 4 |
| Journal total citations count | 1065 |
| Journal impact factor | 2.67 |
| Journal 5 years impact factor | 4.32 |
| Journal cite score | 4.94 |
| Journal h-index | 16 |
| Journal h-index since 2019 | 12 |
Important citations (901)
Eculizumab and hematopoietic stem cell transplantation for the treatment of paroxysmal nocturnal hemoglobinuria associated to aplastic anemia |
|
Complement inhibition for paroxysmal nocturnal hemoglobinuria: where we stand and where we are going |
|
Future strategies of complement inhibition in paroxysmal nocturnal hemoglobinuria |
|
Acute immune toxicity during anti-thymocyte globulin: that's carpa! |
|
Horse anti?thymocyte globulin and eculizumab as concomitant therapeutic approach in an aplastic paroxysmal nocturnal hemoglobinuria patient: go or no?go? |
|
Concurrent treatment of aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: a uk experience |
|
Toward complement inhibition 2.0: next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria |
|
Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? a position paper from the saawp of the ebmt |
|
The nadph oxidase nox2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias |
|
Cd45 and childhood acute lymphoblastic leukemia |
|
Adult pre b-cell acute lymphoblastic leukemia with unusually large proportion of bone marrow cd45 bright/high ssc blasts |
|
Node-pore sensing enables label-free surface-marker profiling of single cells |
|
Targeting the sumo pathway primes all-trans retinoic acid–induced differentiation of nonpromyelocytic acute myeloid leukemias |
|
A pilot study indicating valuation of c?reactive protein for disease outcome in sickle hemoglobin patients of central india |
|
The potential of mhealth as a game changer for the management of sickle cell disease in india |
|
Toward a conversational agent to support the self-management of adults and young adults with sickle cell disease: usability and usefulness study |
|
Functional disability among patients with depressive disorder associated with cognitive impairment at king abdulaziz hospital- makkah. |
|
Sickle cell disease (scd): still here and causing pain, diagnostic & inheritance, district-wise distribution of sickle cell trait among the tribal populations in india |
|
Sickle cell disease in anaemic children in a sierra leonean district hospital: a case series |
|
Fetal haemoglobin: a novel prognostic determinant in sickle cell anaemia |
|